Exchange: NASDAQ·Updated 04:27 PM EST

INVA News

News
all
press releases
Innoviva (NASDAQ:INVA) Stock Picked Up by Analysts at Piper Sandler
Piper Sandler assumed coverage on Innoviva in a report on Wednesday. They set an "overweight" rating and a $29.00 price objective on the stock...
MarketBeat
Innoviva (NASDAQ:INVA) Stock Picked Up by Analysts at Piper Sandler
Piper Sandler assumed coverage on Innoviva in a report on Wednesday. They set an "overweight" rating and a $29.00 price objective on the stock...
MarketBeat
More News
Innoviva, Inc. (NASDAQ:INVA - Free Report) - Research analysts at HC Wainwright raised their FY2026 earnings per share estimates for shares of Innoviva in a research report issued on Friday, November 13th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will earn $2.37...
MarketBeat
Innoviva (NASDAQ:INVA) Sets New 52-Week Low - Here's Why...
MarketBeat
Low P/S ratios, solid fundamentals and manageable debt can help uncover undervalued stocks with upside potential. Explore INVA, DINO, PARR, GPRE and PBF.
Zacks
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
INVA vs. MRK: Which Stock Is the Better Value Option?
Zacks
Innoviva (INVA) delivered earnings and revenue surprises of +2.04% and -6.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Innoviva, Inc. (NASDAQ: INVA) (Innoviva or the Company), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets...
Business Wire
Pfizer (PFE) delivered earnings and revenue surprises of +20.83% and +2.80%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AbbVie (ABBV) delivered earnings and revenue surprises of +2.14% and +0.20%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.